Clinical trial · Interventional
Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma: an Open, Random, Multicenter, Prospective Study
NCT04961138CI-TRIAL-00052695unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of present study is to evaluate whether per-operative neoadjuvant therapy combined with surgery could improve the 1-year disease-free survival of stage III hepatocellular carcinoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Stage III | Hepatocellular Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery | Procedure | — | UNRESOLVED |
| Transhepatic Arterial Chemotherapy And Embolization (TACE) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Neoadjuvant group
- interventionNames
- Procedure: Transhepatic Arterial Chemotherapy And Embolization (TACE)
- type
- ACTIVE_COMPARATOR
- label
- Surgery group
- interventionNames
- Procedure: Surgery
Primary outcomes (1)
- measure
- 1-year disease free survival
- timeFrame
- 1 year
Secondary outcomes (3)
- measure
- 1-year overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18-80 years old, both gender * Confirmed diagnosis of stage III hepatocellular carcinoma(HCC) * Fulfill the criteria of surgery * No other severe comorbidity * Eastern Cooperative Oncology Group score(ECOG) 0-2 * Expected survival \> 3months * Informed consent obtained. Exclusion Criteria: * Received chemoradiotherapy or other antineoplastic drugs * Severe cirrhosis with Child-Pugh score \>10 * Total bilirubin \> 1.5 times upper limit, AST or ALT \> 2times upper limit, indocyanine green retention rate after 15 min(ICG15) \>=40%; * Not fulfill the surgery criteria * Received major surgery within 1month * History of other tumor * Participate other clinical trial within 1month * Drug or alcohol abuse, AIDS * Uncontrollable epileptic seizure or cognitive disorder * Severe allergy * Other unsuitable conditions.
References
Publications (0)
Data not yet available
No reference posted for this study.